The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Open accessAbstract
SUMMARY Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial. We report the existence of a progenitor organization in primary MM that recapitulates maturation stages between B cells and plasma cells and that contributes to clinical PI resistance. Xbp1s− tumor B cells and pre-plasmablasts survive therapeutic PI, preventing cure, while maturation-arrest of MM before plasmablast stage enables progressive disease on PI treatment. Mechanistically, suppression of Xbp1s in MM is shown to induce bortezomib resistance via de-comittment to plasma cell maturation and immunoglobulin production, diminishing endoplasmic reticulum (ER) front loading and cytotoxic susceptibility to PI-induced inhibition of ER-associated degration (ERAD). These results reveal the tumor progenitor structure in MM and highlight its role in therapeutic failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA
Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., & Ron, D. (2002) · Nature · doi:10.1038/415092a · Cited by 2,820
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationCell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
Kim, I., Xu, W., & Reed, J. C. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2755 · Cited by 1,817
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
Self-citationPlasma cell differentiation requires the transcription factor XBP-1
Reimold, A. M., Iwakoshi, N. N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E. M., Friend, D., Grusby, M. J., Alt, F., & Glimcher, L. H. (2001) · Nature · doi:10.1038/35085509 · Cited by 1,305
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Shaffer, A. L., Shapiro-Shelef, M., Iwakoshi, N. N., Lee, A.-H., Qian, S.-B., Zhao, H., Yu, X., Yang, L., Tan, B. K., Rosenwald, A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.010 · Cited by 1,054
A Critical Role for IL-21 in Regulating Immunoglobulin Production
Ozaki, K., Spolski, R., Feng, C. G., Qi, C.-F., Cheng, J., Sher, A., Morse, H. C., Liu, C., Schwartzberg, P. L., & Leonard, W. J. (2002) · Science · doi:10.1126/science.1077002 · Cited by 978
Shapiro-Shelef, M., Lin, K.-I., McHeyzer-Williams, L. J., Liao, J., McHeyzer-Williams, M. G., & Calame, K. (2003) · Immunity · doi:10.1016/s1074-7613(03)00267-x · Cited by 839
Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Self-citationClonal competition with alternating dominance in multiple myeloma
Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Van Wier, S., Blackburn, P. R., Baker, A. S., Dispenzieri, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405985 · Cited by 637
Self-citationProteasome inhibitors disrupt the unfolded protein response in myeloma cells
Lee, A.-H., Iwakoshi, N. N., Anderson, K. C., & Glimcher, L. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1334037100 · Cited by 601
Papandreou, I., Denko, N. C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D. E., Bouley, D. M., Offner, F., Niwa, M., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303099 · Cited by 489
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
Carrasco, D. R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D. E., Zheng, M., Mani, M., Henderson, J., Pinkus, G. S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.015 · Cited by 414
Zhu, K., Dunner, K., & McConkey, D. J. (2010) · Oncogene · doi:10.1038/onc.2009.343 · Cited by 338 · cited 2×
“As a consequence, PI-treated tumor cells characteristically inactivate Eif2a, increase Atf4, and upregulate the expression of UPR genes such as CHOP (DDIT3) and HSPA5 (Chen et al., 2010; Lee et al., 2003; Obeng et al., 2006; Zhu et al., 2010).”
BackgroundMechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Davenport, E. L., Moore, H. E., Dunlop, A. S., Sharp, S. Y., Workman, P., Morgan, G. J., & Davies, F. E. (2007) · Blood · doi:10.1182/blood-2006-11-053728 · Cited by 238
A library of gene expression signatures to illuminate normal and pathological lymphoid biology
Shaffer, A. L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L. T., Davis, R. E., & Staudt, L. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00373.x · Cited by 228
The genetic network controlling plasma cell differentiation
Nutt, S. L., Taubenheim, N., Hasbold, J., Corcoran, L. M., & Hodgkin, P. D. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.010 · Cited by 226
XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells
Hu, C.-C. A., Dougan, S. K., McGehee, A. M., Love, J. C., & Ploegh, H. L. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.117 · Cited by 197
Franke, N. E., Niewerth, D., Assaraf, Y. G., van Meerloo, J., Vojtekova, K., van Zantwijk, C. H., Zweegman, S., Chan, E. T., Kirk, C. J., Geerke, D. P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.256 · Cited by 175
Jourdan, M., Caraux, A., Caron, G., Robert, N., Fiol, G., Reme, T. X., Bolloré, K., Vendrell, J.-P., Gallou, S. L., Mourcin, F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101230 · Cited by 172
Targeting XBP-1 as a novel anti-cancer strategy
Koong, A. C., Chauhan, V., & Romero‐Ramírez, L. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2973 · Cited by 154
Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
Rückrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., Overkleeft, H. S., Kalbacher, H., & Driessen, C. (2009) · Leukemia · doi:10.1038/leu.2009.8 · Cited by 146
Tiedemann, R. E., Zhu, Y. X., Schmidt, J. E., Chang, S., Sereduk, C., Yin, H. H., Mousses, S., & Stewart, A. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2781 · Cited by 139
Self-citationBortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Pérez‐Galán, P., Mora-Jensen, H. I., Weniger, M. A., Shaffer, A. L., Rizzatti, E. G., Chapman, C. M., Mo, C. C., Stennett, L. S., Rader, C. M., Liu, P., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269514 · Cited by 119
Zhu, Y. X., Tiedemann, R. E., Shi, C.-X., Yin, H., Schmidt, J. E., Bruins, L. A., Keats, J. J., Braggio, E., Sereduk, C., Mousses, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-304022 · Cited by 118
Self-citationTiedemann, R. E., Zhu, Y. X., Schmidt, J. E., Yin, H. H., Shi, C.-X., Que, Q. Q., Basu, G. D., Azorsa, D. O., Perkins, L. M., Braggio, E., et al. (2009) · Blood · doi:10.1182/blood-2009-09-243980 · Cited by 108
Self-citationGenome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
Chen, S., Blank, J. L., Peters, T., Liu, X. J., Rappoli, D. M., Pickard, M. D., Menon, S., Yu, J., Driscoll, D. L., Lingaraj, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4428 · Cited by 106
Distinct Steps in Dislocation of Luminal Endoplasmic Reticulum-associated Degradation Substrates
Elkabetz, Y., Shapira, I., Rabinovich, E., & Bar‐Nun, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309938200 · Cited by 95
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
Balsas, P., Galán‐Malo, P., Marzo, I., & Naval, J. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.09.011 · Cited by 90
de Wilt, L. H. A. M., Jansen, G., Assaraf, Y. G., van Meerloo, J., Cloos, J. J., Schimmer, A. D., Chan, E. T., Kirk, C. J., Peters, G. J., & Kruyt, F. A. E. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.009 · Cited by 89
Lichter, D. I., Danaee, H., Pickard, M. D., Tayber, O., Sintchak, M. D., Shi, H., Richardson, P. G. G., Cavenagh, J. D., Bladé, J., Facon, T. T. F., et al. (2012) · Blood · doi:10.1182/blood-2012-05-426924 · Cited by 72
Politou, M., Karadimitris, A., Terpos, E., Kotsianidis, Ι., Apperley, J. F., & Rahemtulla, A. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.014 · Cited by 63
Proteasome β Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics
Wang, L., Kumar, S. K., Fridley, B. L., Kalari, K. R., Moon, I., Pelleymounter, L. L., Hildebrandt, M. A. T., Batzler, A. J., Eckloff, B. W., Wieben, E. D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5150 · Cited by 43
Curability of Multiple Myeloma
Alexanian, R., Delasalle, K. B., Wang, M. L., Thomas, S. K., & Weber, D. (2012) · Bone Marrow Research · doi:10.1155/2012/916479 · Cited by 29
Kotz, J. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.270 · Cited by 1
Cited by
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
The Role of Endoplasmic Reticulum Stress in Human Pathology
Oakes, S. A., & Papa, F. R. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104649 · Cited by 1,581
The generation of antibody-secreting plasma cells
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3795 · Cited by 1,454
Endoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Metadata
- Authors
- Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., & Tiedemann, R. E.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 24
- Issue
- 3
- Pages
- 289-304
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2052645281
- Cited by
- 383
- References
- 40
- FWCI
- 25.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.